Primary effusion lymphoma
MONDO:0018842A large B-cell lymphoma located in the body cavities, characterized by pleural, peritoneal, and pericardial fluid lymphomatous effusions and that is always associated with human herpes virus-8 (HHV-8).
Also known as: PEL, body cavity-based lymphoma, primary Effusion Lymphoma, AIDS-related lymphoma
2015 clinical trials for this condition and its sub-types, 18 tagged with Primary effusion lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
Disease control Recruiting nowThis trial investigates whether long-acting injectable antiretroviral drugs can control HIV better than standard oral pills in adults with AIDS-related lymphoma who are also receiving chemotherapy. Participants will receive one of three HIV treatment strategies—oral pills alone, …
Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Phase 1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Researchers launch long-term observation study for rare KSHV-linked disease
Knowledge-focused Recruiting nowThis study follows 195 adults with KSHV-associated multicentric Castleman's disease (MCD) to better understand how the disease progresses and responds to treatments. Participants receive standard care and regular check-ups over several years. The goal is to improve future treatme…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC